JP2024505723A - ポリオキサゾリン－脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物 - Google Patents

ポリオキサゾリン－脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物 Download PDF

Info

Publication number
JP2024505723A
JP2024505723A JP2023547812A JP2023547812A JP2024505723A JP 2024505723 A JP2024505723 A JP 2024505723A JP 2023547812 A JP2023547812 A JP 2023547812A JP 2023547812 A JP2023547812 A JP 2023547812A JP 2024505723 A JP2024505723 A JP 2024505723A
Authority
JP
Japan
Prior art keywords
lipid
compound
poz
group
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547812A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022173667A5 (https=
JP2024505723A5 (https=
Inventor
ハリス，ジェイ・ミルトン
ベントレー，マイケル
ビエガス，タシー
モレディス，ランドル
シャープ，ロバート・ジェイ
ユン，クンサン
ファン，ジーハオ
ウェイマー，レベッカ
Original Assignee
セリナ・セラピユーテイツクス・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セリナ・セラピユーテイツクス・インコーポレーテツド filed Critical セリナ・セラピユーテイツクス・インコーポレーテツド
Publication of JP2024505723A publication Critical patent/JP2024505723A/ja
Publication of JPWO2022173667A5 publication Critical patent/JPWO2022173667A5/ja
Publication of JP2024505723A5 publication Critical patent/JP2024505723A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
JP2023547812A 2021-02-09 2022-02-04 ポリオキサゾリン－脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物 Pending JP2024505723A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163147470P 2021-02-09 2021-02-09
US63/147,470 2021-02-09
US17/665,190 US12233132B2 (en) 2021-02-09 2022-02-04 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same
US17/665,190 2022-02-04
PCT/US2022/015314 WO2022173667A1 (en) 2021-02-09 2022-02-04 Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

Publications (3)

Publication Number Publication Date
JP2024505723A true JP2024505723A (ja) 2024-02-07
JPWO2022173667A5 JPWO2022173667A5 (https=) 2025-03-06
JP2024505723A5 JP2024505723A5 (https=) 2025-03-06

Family

ID=82703446

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547812A Pending JP2024505723A (ja) 2021-02-09 2022-02-04 ポリオキサゾリン－脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物

Country Status (9)

Country Link
US (2) US12233132B2 (https=)
EP (1) EP4291242A4 (https=)
JP (1) JP2024505723A (https=)
KR (1) KR20230144574A (https=)
CN (1) CN117098558A (https=)
AU (1) AU2022219902A1 (https=)
CA (1) CA3206128A1 (https=)
IL (1) IL304773A (https=)
WO (1) WO2022173667A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
MX2024002726A (es) 2021-09-03 2024-03-20 CureVac SE Nuevas nanoparticulas lipidicas para la administracion de acidos nucleicos.
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
US20250099614A1 (en) 2022-01-28 2025-03-27 CureVac SE Nucleic acid encoded transcription factor inhibitors
CN118900701A (zh) * 2022-01-31 2024-11-05 盖纳万科学有限公司 聚(烷基噁唑啉)-脂质缀合物及含有聚(烷基噁唑啉)-脂质缀合物的脂质颗粒
AU2023425729A1 (en) * 2023-01-20 2025-07-17 Serina Therapeutics (Al), Inc. Targeting of antigen-presenting cells by nanoparticles containing polyoxazoline-lipid conjugates
KR20250153298A (ko) 2023-03-08 2025-10-24 큐어백 에스이 핵산 전달을 위한 신규의 지질 나노입자 제형
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024230934A1 (en) 2023-05-11 2024-11-14 CureVac SE Therapeutic nucleic acid for the treatment of ophthalmic diseases
IL324725A (en) * 2023-06-15 2026-01-01 Serina Therapeutics Al Inc Poly(oxazoline) conjugates with pendant cationic groups and lipid nanoparticles and polyplexes comprising them
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025137256A1 (en) * 2023-12-20 2025-06-26 Wu Nian Polyoxazoline-carbohydrate-lipid conjugates
WO2025134071A1 (en) 2023-12-22 2025-06-26 Sanofi Malic and glutaric acid based ionizable lipids
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025196065A1 (en) 2024-03-20 2025-09-25 Sanofi Novel homocysteine based lipids and their use for delivery of nucleic acids
WO2025257084A1 (en) * 2024-06-10 2025-12-18 Isar Bioscience Gmbh Lipid composition
WO2026008743A1 (en) 2024-07-02 2026-01-08 Sanofi Pasteur Inc. Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid
WO2026053147A1 (en) 2024-09-05 2026-03-12 Sanofi Pasteur Inc. Helper lipids and lnp compositions comprising same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02247227A (ja) * 1989-03-20 1990-10-03 Kao Corp 新規オリゴマー、その製法および用途
JPH08507523A (ja) * 1993-03-03 1996-08-13 シキュース ファーマシューティカルズ，インコーポレイテッド 脂質−ポリマー結合体およびリポソーム
JPH08286313A (ja) * 1995-04-14 1996-11-01 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2011527727A (ja) * 2008-07-10 2011-11-04 セリナ・セラピユーテイツクス・インコーポレーテツド 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
US20110313017A1 (en) * 2010-01-13 2011-12-22 Protiva Biotherapeutics, Inc. Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US20020001614A1 (en) * 2000-02-10 2002-01-03 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof
KR101508621B1 (ko) 2007-02-28 2015-04-07 세리나 쎄라퓨틱스, 인코포레이티드 활성화된 폴리옥사졸린 및 이를 포함하는 조성물
US8088884B2 (en) 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
SG186085A1 (en) * 2010-06-03 2013-01-30 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
PT3970742T (pt) * 2010-08-31 2022-06-27 Glaxosmithkline Biologicals Sa Lipossomas peguilados para entrega de arn codificador de imunogénio
US8383093B1 (en) 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
US12485181B2 (en) * 2019-06-28 2025-12-02 Serina Therapeutics (Al), Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02247227A (ja) * 1989-03-20 1990-10-03 Kao Corp 新規オリゴマー、その製法および用途
JPH08507523A (ja) * 1993-03-03 1996-08-13 シキュース ファーマシューティカルズ，インコーポレイテッド 脂質−ポリマー結合体およびリポソーム
JPH08286313A (ja) * 1995-04-14 1996-11-01 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
JP2011527727A (ja) * 2008-07-10 2011-11-04 セリナ・セラピユーテイツクス・インコーポレーテツド 不活性末端基を有するポリオキサゾリン類、保護された開始基から調製されるポリオキサゾリン類及び関連化合物
US20110313017A1 (en) * 2010-01-13 2011-12-22 Protiva Biotherapeutics, Inc. Snalp formulations containing polyoxazoline-dialkyloxypropyl conjugates

Also Published As

Publication number Publication date
CA3206128A1 (en) 2022-08-18
EP4291242A4 (en) 2025-11-26
AU2022219902A1 (en) 2023-08-10
US20240108750A1 (en) 2024-04-04
US12233132B2 (en) 2025-02-25
EP4291242A1 (en) 2023-12-20
CN117098558A (zh) 2023-11-21
WO2022173667A1 (en) 2022-08-18
KR20230144574A (ko) 2023-10-16
IL304773A (en) 2023-09-01
US20220249695A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
JP2024505723A (ja) ポリオキサゾリン－脂質コンジュゲート並びにそれらを含む脂質ナノ粒子及び医薬組成物
US20230132645A1 (en) Lipid membrane structure for delivery into sirna cell
CN115362143A (zh) 可离子化脂质
US10182987B2 (en) Lipid membrane structure for intracellular delivery of siRNA
JP2024512770A (ja) 遺伝子送達における非ウイルスベクターとしての樹状構造
WO2024187160A2 (en) Oxyanion azide-benzaldehyde acetal acid-degradable lipids
JP2025508877A (ja) アミノ脂質化合物、その調製方法、その組成物およびその使用
HK40103124A (zh) 聚恶唑啉-脂质缀合物及包含其的脂质纳米颗粒和药物组合物
KR20250139323A (ko) 폴리옥사졸린-지질 접합체를 함유하는 나노입자에 의한 항원-제시 세포의 표적화
US20250352664A1 (en) Meth0ds of administering lipid nanoparticles including poly(ethyloxazoline)-lipid conjugates without raising immune response to polymer
KR102805255B1 (ko) 신규한 이온화지질 및 이를 이용한 지질나노입자 조성물
JP7690222B2 (ja) 動力学的制御が可能なアジュバントを含むｍＲＮＡワクチン
CN117203186A (zh) 一种含有二硫键的脂质化合物及其组合物
KR20260026532A (ko) 펜던트 양이온성 기를 갖는 폴리(옥사졸린) 접합체 및 이를 포함하는 지질 나노입자 및 폴리플렉스
WO2025261607A1 (en) Particles, compositions and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260420